Versartis, Inc. (VSAR) stock prices updated...
 

Versartis, Inc. stock price

Versartis, Inc. latest news:


  • 09/21/2017 15:59:28

    Versartis growth hormone drug fails key study, shares sink

    Sept 21 (Reuters) - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

  • 09/21/2017 15:00:23

    Versartis shares halted

    Shares of Versartis Inc. were halted late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc. , in a study focusing on pediatric growth-hormone deficiency. "We are very surprised and disappointed to learn the outcome," Chief Executive Jay Shepard said in Thursday's announcement, adding that the company planned to provide a corporate update later this year. Versartis shares have gained 27% in the past three months, more than 10 times the gains for the S&P 500 Index in the same period, and nearly 45% so far this year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Vertex Energy, IncVTNR | Vertex Pharmaceuticals IncorporatedVRTX | Vestin Realty Mortgage I, Inc.VRTA | Vestin Realty Mortgage II, Inc.VRTB | Viacom Inc.VIA | Viacom Inc.VIAB | ViaSat, Inc.VSAT | Viavi Solutions Inc.VIAV | Vical IncorporatedVICL | Vicor CorporationVICR |